- Home
- NG vs DNTH Comparison
NG vs DNTH Comparison
Compare NG & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NG | DNTH |
|---|---|---|
| Founded | 1984 | 2015 |
| Country | Canada | United States |
| Employees | N/A | 92 |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 4.8B |
| IPO Year | 2002 | 2018 |
Fundamental Metrics
Financial Performance| Metric | NG | DNTH |
|---|---|---|
| Price | $8.61 | $87.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 13 |
| Target Price | $12.22 | ★ $121.00 |
| AVG Volume (30 Days) | ★ 2.9M | 753.9K |
| Earning Date | 04-01-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,036,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $29.48 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.37 | $16.77 |
| 52 Week High | $14.40 | $96.50 |
Technical Indicators
Market Signals| Indicator | NG | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 40.55 | 54.75 |
| Support Level | $7.85 | $33.94 |
| Resistance Level | $10.44 | $88.45 |
| Average True Range (ATR) | 0.60 | 3.74 |
| MACD | -0.04 | -1.19 |
| Stochastic Oscillator | 3.75 | 33.16 |
Price Performance
Historical ComparisonAbout NG Novagold Resources Inc.
Novagold Resources Inc operates in the gold mining industry, focused on advancing the Donlin Gold project in Alaska. The Donlin Gold project is held by Donlin Gold LLC (Donlin Gold), a limited liability company owned equally by wholly owned subsidiaries of NOVAGOLD and Barrick Gold Corporation (Barrick). The company includes exploration and development activities of gold and other precious metals.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.